Medicare Program; Application by the National Association of Boards of Pharmacy (NABP) for Continued CMS Approval of its Home Infusion Therapy (HIT) Accreditation Program, 32434-32435 [2024-09044]
Download as PDF
32434
Federal Register / Vol. 89, No. 82 / Friday, April 26, 2024 / Notices
Frequency: Occasionally; Affected
Public: Business or other for-profit and
not-for-profit institutions; Number of
Respondents; 78,258; Total Annual
Responses; 78,258; Total Annual Hours:
22,780. (For policy questions regarding
this collection contact Frank Whelan at
410–786–1302.)
William N. Parham, III
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–09040 Filed 4–25–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3464–PN]
Medicare Program; Application by the
National Association of Boards of
Pharmacy (NABP) for Continued CMS
Approval of its Home Infusion Therapy
(HIT) Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice with request for
comment.
AGENCY:
This notice acknowledges the
receipt of an application from the
National Association of Boards of
Pharmacy (NABP) for continued
approval by the Centers for Medicare &
Medicaid Services (CMS) of NABP’s
national accrediting organization
program for suppliers providing home
infusion therapy (HIT) services and that
wish to participate in the Medicare or
Medicaid programs. The statute requires
that within 60 days of receipt of an
organization’s complete application,
CMS will publish a notice that identifies
the national accrediting body making
the request, describes the nature of the
request, and provides at least a 30-day
public comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, by May
28, 2024.
ADDRESSES: In commenting, refer to file
code CMS–3464–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
20:31 Apr 25, 2024
Jkt 262001
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3464–PN, P.O. Box 8016,
Baltimore, MD 21244–8010.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3464–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Shannon Freeland, (410) 786–4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments. We will not post on
Regulations.gov public comments that
make threats to individuals or
institutions or suggest that the
individual will take actions to harm the
individual. We continue to encourage
individuals not to submit duplicative
comments. We will post acceptable
comments from multiple unique
commenters even if the content is
identical or nearly identical to other
comments.
I. Background
Home infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted December 13, 2016) added
section 1861(iii) to the Social Security
Act (the Act), establishing a new
Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines
‘‘home infusion therapy’’ as professional
services, including nursing services;
training and education not otherwise
covered under the Durable Medical
Equipment (DME) benefit; remote
monitoring; and other monitoring
services. HIT must be furnished by a
qualified HIT supplier and furnished in
the individual’s home. The individual
must:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
designated AOs. These statutory factors
are as follows:
• The ability of the organization to
conduct timely reviews of accreditation
applications.
• The ability of the organization to
take into account the capacities of
suppliers located in a rural area (as
defined in section 1886(d)(2)(D) of the
Act).
• Whether the organization has
established reasonable fees to be
charged to suppliers applying for
accreditation.
• Such other factors as the Secretary
determines appropriate.
Section 1834(u)(5)(B) of the Act
requires the Secretary to designate AOs
to accredit HIT suppliers furnishing HIT
no later than January 1, 2021. Section
1861(iii)(3)(D)(i)(III) of the Act requires
a ‘‘qualified home infusion therapy
supplier’’ to be accredited by a CMSapproved AO, pursuant to section
1834(u)(5) of the Act.
On March 1, 2019, we published a
solicitation notice entitled, ‘‘Medicare
Program; Solicitation of Independent
Accrediting Organizations to Participate
in the Home Infusion Therapy Supplier
Accreditation Program’’ (84 FR 7057).
This notice informed national AOs that
accredit HIT suppliers of an opportunity
to submit applications to participate in
the HIT supplier accreditation program.
We stated that complete applications
would be considered for the January 1,
2021 designation deadline if received by
February 1, 2020. Regulations for the
approval and oversight of AOs for HIT
organizations are located at 42 CFR part
488, subpart L. The requirements for
HIT suppliers are located at 42 CFR part
486, subpart I.
II. Approval of Deeming Organization
Section 1834(u)(5) of the Act and
regulations at 42 CFR 488.1010 require
that our findings concerning review and
approval of a national accrediting
E:\FR\FM\26APN1.SGM
26APN1
Federal Register / Vol. 89, No. 82 / Friday, April 26, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
organization’s requirements consider,
among other factors, the applying
accrediting organization’s requirements
for accreditation; survey procedures;
resources for conducting required
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide CMS with the
necessary data.
Our rules at 42 CFR 488.1020(a)
require that we publish, after receipt of
an organization’s complete application,
a notice that identifies the national
accrediting body making the request,
describes the nature of the request, and
provides at least a 30-day public
comment period. Pursuant to our rules
at 42 CFR 488.1010(d), we have 210
days from the receipt of a complete
application to publish notice of
approval or denial of the application.
The purpose of this proposed notice
is to inform the public of the National
Association of Boards of Pharmacy’s
(NABP’s) request for CMS’ continued
recognition of its HIT accreditation
program. This notice also solicits public
comment on whether NABP’s
requirements meet or exceed the
Medicare requirements of participation
for HIT services.
III. Evaluation of Deeming Authority
Request
In the April 28, 2020 Federal
Register, we published NABP’s initial
application for recognition as an
accreditation organization for HIT (85
FR 23519). On September 28, 2020, we
published notification of their approval
as such an organization, effective
September 26, 2020 through September
26, 2024 (85 FR 60793). NABP has since
submitted all the necessary materials to
enable us to make a determination
concerning its request for continued
recognition of its HIT accreditation
program. This application was
determined to be complete on February
28, 2024. Under section 1834(u)(5) of
the Act and 42 CFR 488.1010
(Application and re-application
procedures for national home infusion
therapy accrediting organizations), our
review and evaluation of NABP will be
conducted in accordance with, but not
necessarily limited to, the following
factors:
• The equivalency of NABP’s
standards for HIT as compared with
CMS’ HIT requirements for participation
in the Medicare program.
• NABP’s survey process to
determine the following:
++ The composition of the survey
team, surveyor qualifications, and the
VerDate Sep<11>2014
20:31 Apr 25, 2024
Jkt 262001
ability of the organization to provide
continuing surveyor training.
++ The comparability of NABP’s to
CMS’ standards and processes,
including survey frequency, and the
ability to investigate and respond
appropriately to complaints against
accredited facilities.
++ NABP’s processes and procedures
for monitoring a HIT supplier found out
of compliance with NABP’s program
requirements.
++ NABP’s capacity to report
deficiencies to the surveyed facilities
and respond to the facility’s plan of
correction in a timely manner.
++ NABP’s capacity to provide CMS
with electronic data and reports
necessary for effective assessment and
interpretation of the organization’s
survey process.
++ The adequacy of NABP’s staff and
other resources, and its financial
viability.
++ NABP’s capacity to adequately
fund required surveys.
++ NABP’s policies with respect to
whether surveys are announced or
unannounced, to ensure that surveys are
unannounced.
++ NABP’s agreement to provide
CMS with a copy of the most current
accreditation survey together with any
other information related to the survey
as CMS may require (including
corrective action plans).
++ NABP’s policies and procedures
to avoid conflicts of interest, including
the appearance of conflicts of interest,
involving individuals who conduct
surveys, audits or participate in
accreditation decisions.
++ NABP’s agreement or policies for
voluntary and involuntary termination
of HIT suppliers.
++ NABP’s agreement or policies for
voluntary and involuntary termination
of the HIT AO program.
IV. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping, or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public
comments, we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
32435
this preamble, and, when we proceed
with a subsequent document, we will
respond to the comments in the
preamble to that document.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Trenesha Fultz-Mimms, who
is the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2024–09044 Filed 4–25–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–P–0015A]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
June 25, 2024.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
SUMMARY:
E:\FR\FM\26APN1.SGM
26APN1
Agencies
[Federal Register Volume 89, Number 82 (Friday, April 26, 2024)]
[Notices]
[Pages 32434-32435]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09044]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3464-PN]
Medicare Program; Application by the National Association of
Boards of Pharmacy (NABP) for Continued CMS Approval of its Home
Infusion Therapy (HIT) Accreditation Program
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice with request for comment.
-----------------------------------------------------------------------
SUMMARY: This notice acknowledges the receipt of an application from
the National Association of Boards of Pharmacy (NABP) for continued
approval by the Centers for Medicare & Medicaid Services (CMS) of
NABP's national accrediting organization program for suppliers
providing home infusion therapy (HIT) services and that wish to
participate in the Medicare or Medicaid programs. The statute requires
that within 60 days of receipt of an organization's complete
application, CMS will publish a notice that identifies the national
accrediting body making the request, describes the nature of the
request, and provides at least a 30-day public comment period.
DATES: To be assured consideration, comments must be received at one of
the addresses provided below, by May 28, 2024.
ADDRESSES: In commenting, refer to file code CMS-3464-PN.
Comments, including mass comment submissions, must be submitted in
one of the following three ways (please choose only one of the ways
listed):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the ``Submit a
comment'' instructions.
2. By regular mail. You may mail written comments to the following
address ONLY: Centers for Medicare & Medicaid Services, Department of
Health and Human Services, Attention: CMS-3464-PN, P.O. Box 8016,
Baltimore, MD 21244-8010.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments to
the following address ONLY: Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Attention: CMS-3464-PN, Mail
Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
For information on viewing public comments, see the beginning of
the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Shannon Freeland, (410) 786-4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following
website as soon as possible after they have been received: https://www.regulations.gov. Follow the search instructions on that website to
view public comments. We will not post on Regulations.gov public
comments that make threats to individuals or institutions or suggest
that the individual will take actions to harm the individual. We
continue to encourage individuals not to submit duplicative comments.
We will post acceptable comments from multiple unique commenters even
if the content is identical or nearly identical to other comments.
I. Background
Home infusion therapy (HIT) is a treatment option for Medicare
beneficiaries with a wide range of acute and chronic conditions.
Section 5012 of the 21st Century Cures Act (Pub. L. 114-255, enacted
December 13, 2016) added section 1861(iii) to the Social Security Act
(the Act), establishing a new Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines ``home infusion therapy'' as
professional services, including nursing services; training and
education not otherwise covered under the Durable Medical Equipment
(DME) benefit; remote monitoring; and other monitoring services. HIT
must be furnished by a qualified HIT supplier and furnished in the
individual's home. The individual must:
Be under the care of an applicable provider (that is,
physician, nurse practitioner, or physician assistant); and
Have a plan of care established and periodically reviewed
by a physician in coordination with the furnishing of home infusion
drugs under Part B, that prescribes the type, amount, and duration of
infusion therapy services that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act requires that a
qualified HIT supplier be accredited by an accrediting organization
(AO) designated by the Secretary in accordance with section 1834(u)(5)
of the Act. Section 1834(u)(5)(A) of the Act identifies factors for
designating AOs and in reviewing and modifying the list of designated
AOs. These statutory factors are as follows:
The ability of the organization to conduct timely reviews
of accreditation applications.
The ability of the organization to take into account the
capacities of suppliers located in a rural area (as defined in section
1886(d)(2)(D) of the Act).
Whether the organization has established reasonable fees
to be charged to suppliers applying for accreditation.
Such other factors as the Secretary determines
appropriate.
Section 1834(u)(5)(B) of the Act requires the Secretary to
designate AOs to accredit HIT suppliers furnishing HIT no later than
January 1, 2021. Section 1861(iii)(3)(D)(i)(III) of the Act requires a
``qualified home infusion therapy supplier'' to be accredited by a CMS-
approved AO, pursuant to section 1834(u)(5) of the Act.
On March 1, 2019, we published a solicitation notice entitled,
``Medicare Program; Solicitation of Independent Accrediting
Organizations to Participate in the Home Infusion Therapy Supplier
Accreditation Program'' (84 FR 7057). This notice informed national AOs
that accredit HIT suppliers of an opportunity to submit applications to
participate in the HIT supplier accreditation program. We stated that
complete applications would be considered for the January 1, 2021
designation deadline if received by February 1, 2020. Regulations for
the approval and oversight of AOs for HIT organizations are located at
42 CFR part 488, subpart L. The requirements for HIT suppliers are
located at 42 CFR part 486, subpart I.
II. Approval of Deeming Organization
Section 1834(u)(5) of the Act and regulations at 42 CFR 488.1010
require that our findings concerning review and approval of a national
accrediting
[[Page 32435]]
organization's requirements consider, among other factors, the applying
accrediting organization's requirements for accreditation; survey
procedures; resources for conducting required surveys; capacity to
furnish information for use in enforcement activities; monitoring
procedures for provider entities found not in compliance with the
conditions or requirements; and ability to provide CMS with the
necessary data.
Our rules at 42 CFR 488.1020(a) require that we publish, after
receipt of an organization's complete application, a notice that
identifies the national accrediting body making the request, describes
the nature of the request, and provides at least a 30-day public
comment period. Pursuant to our rules at 42 CFR 488.1010(d), we have
210 days from the receipt of a complete application to publish notice
of approval or denial of the application.
The purpose of this proposed notice is to inform the public of the
National Association of Boards of Pharmacy's (NABP's) request for CMS'
continued recognition of its HIT accreditation program. This notice
also solicits public comment on whether NABP's requirements meet or
exceed the Medicare requirements of participation for HIT services.
III. Evaluation of Deeming Authority Request
In the April 28, 2020 Federal Register, we published NABP's initial
application for recognition as an accreditation organization for HIT
(85 FR 23519). On September 28, 2020, we published notification of
their approval as such an organization, effective September 26, 2020
through September 26, 2024 (85 FR 60793). NABP has since submitted all
the necessary materials to enable us to make a determination concerning
its request for continued recognition of its HIT accreditation program.
This application was determined to be complete on February 28, 2024.
Under section 1834(u)(5) of the Act and 42 CFR 488.1010 (Application
and re-application procedures for national home infusion therapy
accrediting organizations), our review and evaluation of NABP will be
conducted in accordance with, but not necessarily limited to, the
following factors:
The equivalency of NABP's standards for HIT as compared
with CMS' HIT requirements for participation in the Medicare program.
NABP's survey process to determine the following:
++ The composition of the survey team, surveyor qualifications, and
the ability of the organization to provide continuing surveyor
training.
++ The comparability of NABP's to CMS' standards and processes,
including survey frequency, and the ability to investigate and respond
appropriately to complaints against accredited facilities.
++ NABP's processes and procedures for monitoring a HIT supplier
found out of compliance with NABP's program requirements.
++ NABP's capacity to report deficiencies to the surveyed
facilities and respond to the facility's plan of correction in a timely
manner.
++ NABP's capacity to provide CMS with electronic data and reports
necessary for effective assessment and interpretation of the
organization's survey process.
++ The adequacy of NABP's staff and other resources, and its
financial viability.
++ NABP's capacity to adequately fund required surveys.
++ NABP's policies with respect to whether surveys are announced or
unannounced, to ensure that surveys are unannounced.
++ NABP's agreement to provide CMS with a copy of the most current
accreditation survey together with any other information related to the
survey as CMS may require (including corrective action plans).
++ NABP's policies and procedures to avoid conflicts of interest,
including the appearance of conflicts of interest, involving
individuals who conduct surveys, audits or participate in accreditation
decisions.
++ NABP's agreement or policies for voluntary and involuntary
termination of HIT suppliers.
++ NABP's agreement or policies for voluntary and involuntary
termination of the HIT AO program.
IV. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public comments, we normally receive
on Federal Register documents, we are not able to acknowledge or
respond to them individually. We will consider all comments we receive
by the date and time specified in the DATES section of this preamble,
and, when we proceed with a subsequent document, we will respond to the
comments in the preamble to that document.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Trenesha Fultz-Mimms, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2024-09044 Filed 4-25-24; 8:45 am]
BILLING CODE 4120-01-P